Xenetic Reports Q3 2026 Results, $1.7 Million Net Loss

Xenetic reported third-quarter 2026 royalty revenue of approximately $0.7 million and a net loss of approximately $1.7 million, or $0.72 per share. The company also highlighted a proposed share exchange with Santersus AG that is expected to create a clinical-stage company focused on targeting neutr…